In fact, Santanam et al. have developed a mouse model of early onset indolent CD5+ B-CLL by targeted overexpression of miR-29 in B-lymphocytes under control of the Eμ enhancer [46]. The gene discussed is CD5; the disease is B-cell chronic lymphocytic leukemia.